Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance

Full-Year Guidance Raised Again With Wegovy Factored In

Executive Summary

The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus. 

You may also be interested in...



Novo Nordisk To 'Double Obesity Drug Sales by 2025'

Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.

Novo's Saxenda bags FDA approval for weight management

With US FDA approval for Saxenda (liraglutide) Novo Nordisk could be a contender in the market for prescription weight loss drugs, which so far has yielded disappointing sales from oral obesity therapies approved in the US since 2012 starting with Belviq (lorcaserin) from Arena Pharmaceuticals.

Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel